edasalonexent
Small moleculeexperimental
Clinical trial activity
6 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
3
Phase 3
2
Phase 4
0
Earliest trial started Dec 1, 2011 (NCT01511900)
Timeline
Indications
Mechanism of action
- NF-kappaB inhibitor alphaINHIBITOR
NFKBIA inhibitor
- Nuclear factor NF-kappa-B complexINHIBITOR
Nuclear factor NF-kappa-B complex inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)NCCNC(=O)c1ccccc1O- Mol. weight
- 490.69 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3786673 ↗
Also known as
- cat 1004
- cat 1004
- cat-1004
- cat-1004
- edasalonexent
- edasalonexent
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04543370 | Phase 1 | Aug 8, 2020 | Catabasis |
| NCT03917719 | Phase 3 | Mar 14, 2019 | Catabasis |
| NCT03703882 | Phase 3 | Oct 2, 2018 | Catabasis |
| NCT02439216 | Phase 1/Phase 2 (Phase 2) | Apr 1, 2016 | Catabasis |
| NCT01670773 | Phase 1 | Aug 1, 2012 | Catabasis |
| NCT01511900 | Phase 1 | Dec 1, 2011 | Catabasis |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Catabasis | For profit | 6 | 6 | 3 | 2011 |
1 organizations
Page 1 / 1